Based on the Catalyst Pharmaceuticals Inc stock forecast from 5 analysts, the average analyst target price for Catalyst Pharmaceuticals Inc is USD 30.88 over the next 12 months. Catalyst Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Catalyst Pharmaceuticals Inc is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Catalyst Pharmaceuticals Inc’s stock price was USD 21.39. Catalyst Pharmaceuticals Inc’s stock price has changed by -7.16% over the past week, +0.71% over the past month and +54.89% over the last year.
No recent analyst target price found for Catalyst Pharmaceuticals Inc
No recent average analyst rating found for Catalyst Pharmaceuticals Inc
Company Overview Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida. Read Less
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phospha...Read More
Frequently Asked Questions About Catalyst Pharmaceuticals Inc (CPRX) Stock
Based on ratings from 5 analysts Catalyst Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on CPRX's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for CPRX is USD 30.88 over the next 12 months. The maximum analyst target price is USD 36 while the minimum anlayst target price is USD 26.
CPRX stock's Price/Earning ratio is 17.46.
Our analysis grades CPRX stock's Price / Earning ratio at F. This means that CPRX stock's Price/Earning ratio is above 68% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CPRX may be a overvalued for its sector.
The last closing price of CPRX's stock was USD 21.39.
The most recent market capitalization for CPRX is USD 2.46B.
Based on targets from 5 analysts, the average taret price for CPRX is projected at USD 30.88 over the next 12 months.
This means that CPRX's stock price may go up by +44.34% over the next 12 months.
We can't find any ETFs which contains Catalyst Pharmaceuticals Inc's stock.
As per our most recent records Catalyst Pharmaceuticals Inc has 167 Employees.
Catalyst Pharmaceuticals Inc's registered address is 355 Alhambra Circle, Coral Gables, FL, United States, 33134.
You can get more information about it from Catalyst Pharmaceuticals Inc's website at https://www.catalystpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Catalyst Pharmaceuticals Inc (CPRX) Stock
Based on ratings from 5 analysts Catalyst Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on CPRX's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for CPRX is USD 30.88 over the next 12 months. The maximum analyst target price is USD 36 while the minimum anlayst target price is USD 26.
CPRX stock's Price/Earning ratio is 17.46.
Our analysis grades CPRX stock's Price / Earning ratio at F. This means that CPRX stock's Price/Earning ratio is above 68% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CPRX may be a overvalued for its sector.
The last closing price of CPRX's stock was USD 21.39.
The most recent market capitalization for CPRX is USD 2.46B.
Based on targets from 5 analysts, the average taret price for CPRX is projected at USD 30.88 over the next 12 months.
This means that CPRX's stock price may go up by +44.34% over the next 12 months.
We can't find any ETFs which contains Catalyst Pharmaceuticals Inc's stock.
As per our most recent records Catalyst Pharmaceuticals Inc has 167 Employees.
Catalyst Pharmaceuticals Inc's registered address is 355 Alhambra Circle, Coral Gables, FL, United States, 33134.
You can get more information about it from Catalyst Pharmaceuticals Inc's website at https://www.catalystpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CPRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
